Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-adMSCs for COVID-19
NCT04362189Phase 2Terminated
- Sponsor
- Hope Biosciences
- Start
- Jun 2020
- Primary completion
- Sep 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic HB-adMSCs in coronavirus disease 2019 (COVID-19), sponsored by Hope Biosciences. Primary endpoints: Tumor Necrosis Factor-Alpha at Day 10, Interleukin-10 at Day 10 and 4 more. Started Jun 2020; status: terminated.
02
Drugs
allogeneic HB-adMSCs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04362189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362189.